Dual-coated lactic acid bacteria: An emerging innovative technology in the field of probiotics

Future Microbiology

Volumn 11, Issue 3, 2016, Pages 467-475

  Alvarez Calatayud, Guillermo ^a   Margolles, Abelardo ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b DEPARTMENT OF MICROBIOLOGY AND BIOCHEMISTRY OF DAIRY PRODUCTS   (Spain)

Author keywords

antibiotic related diarrhea; atopic dermatitis; diarrhea; dual coated probiotic formulation; irritable bowel syndrome; lactic acid bacteria; probiotics

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT; ANTIINFECTIVE AGENT; POLYSACCHARIDE; PROTEIN;

ACUTE DIARRHEA; ANTIBIOTIC ASSOCIATED DIARRHEA; ATOPIC DERMATITIS; BACTERIAL SURVIVAL; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM LONGUM; CONSTIPATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMIDITY; INTESTINE; IRRITABLE COLON; LACTIC ACID BACTERIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII SUBSP. LACTIS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; NONHUMAN; PRESSURE; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS THERMOPHILUS; TEMPERATURE; CHEMISTRY; DERMATITIS, ATOPIC; DIARRHEA; GASTROINTESTINAL TRACT; IRRITABLE BOWEL SYNDROME; LACTOBACILLALES; MICROBIAL VIABILITY; MICROBIOLOGY; PH; PHYSIOLOGY; STOMACH ACID;

ANTI-BACTERIAL AGENTS; CONSTIPATION; DERMATITIS, ATOPIC; DIARRHEA; GASTRIC ACID; GASTROINTESTINAL TRACT; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; IRRITABLE BOWEL SYNDROME; LACTOBACILLALES; MICROBIAL VIABILITY; POLYSACCHARIDES; PROBIOTICS; PROTEINS;

EID: 84962374142     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.150     Document Type: Review

References (46)

1. FAO/WHO. Guidelines for the Evaluation of Probiotics in Food. Food and Agriculture Organization of the United Nations/WHO, London, UK (2002).
2. Hill C, Guarner F, Reid G et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11(8), 506-514 (2014).
3. Solanki HK, Pawar DD, Shah DA et al. Development of microencapsulation delivery system for long-term preservation of probiotics as biotherapeutics agent. Biomed. Res. Int. 2013, 620719 (2013).
4. Pandey V, Berwal V, Solanki N, Malik N. Probiotics: healthy bugs and nourishing elements of diet. J. Int. Soc. Prev. Community Dent. 5(2), 81-87 (2015).
5. Amara AA, Shibl A. Role of probiotics in health improvement, infection control and disease treatment and management. Saudi Pharm. J. 23(2), 107-114 (2015).
6. Kopp-Hoolihan L. Prophylactic and therapeutic uses of probiotics: a review. J. Am. Diet. Assoc. 101(2), 229-238 (2001).
7. Liévin-Le Moal V, Servin AL. Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clin. Microbiol. Rev. 27(2), 167-199 (2014).
8. Petschow B, Doré J, Hibberd P et al. Probiotics, prebiotics, and the host microbiome: the science of translation. Ann. NY Acad. Sci. 1306(12), 1-17 (2013).
9. Bermúdez-Humarán LG, Aubry C, Motta JP et al. Engineering lactococci and lactobacilli for human health. Curr. Opin, Microbiol. 16(3), 278-283 (2013).
10. Timmerman HM, Niers LE, Ridwan BU et al. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. Clin. Nutr. 26(4), 450-459 (2007).
11. Betta P. Not all probiotics are the same: gut microbiota modulation with a multistrain probiotics. N. Am. J. Med. Sci. 6(1), 58-59 (2014).
12. Mikelsaar M, Lazar V, Onderdonk B, Donelli G. Do probiotic preparations for humans really have efficacy? Microb. Ecol. Health Dis. 22, 10128 (2011).
13. Tsai CC, Liang HW, Yu B, Hsieh CC, Hwang CF, Chen MH. The relative efficacy of different strain combinations of lactic acid bacteria in the reduction of population of Samonella enterica Typhimurium in the livers and spleens of mice. FEMS Immunol. Med. Microbiol. 63(1), 44-53 (2011).
14. Chapman CM, Gibson GR, Rowland I. Health benefits of probiotics: are mixtures more effective than single strains? Eur. J. Nutr. 50(1), 1-17 (2011).
15. Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr. Issues Intest. Microbiol. 2(2), 43-53 (2001).
16. Ouwehand AC, Isolauri E, Kirjavainen PV, Tölkko S, Salminen SJ. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. Delbrueckii subsp. bulgaricus. Lett. Appl. Microbiol. 30(1), 10-13 (2000).
17. Timmerman HM, Koning CJ, Mulder L, Rombouts FM, Beynen AC. Monostrain multistrain and multispecies probiotic - a comparison of functionality and efficacy. Int. J. Food Microbiol. 96(3), 219-233 (2004).
18. Champagne CP, Raymond Y, Tompkins TA. The determination of viable counts in probiotic cultures microencapsulated by spray-coating. Food Microbiol. 27(8). 1104-1111 (2010).
19. Khan SH, Ansari FA. Probiotics - the friendly bacteria with market potential in global market. Pak. J. Pharm. Sci. 20(1), 76-82 (2007).
20. Kang JY, Lee DK, Park E, Kim MJ, Lee JS, Seo JG et al. Dual coating improves the survival of probiotic Bifidobacterium strains during exposure to simulated gastro-intestinal conditions. Korean J. Microbiol. 49(3), 275-281 (2013).
21. Cha MY, Chung MJ, Lee KO, Ha NJ. Comparison of dual coated (DuolacTM) and uncoated lactic acid bacteria from potential probiotics. Biotechnol. Biotechnol. Eq. 25(3), 2489-2493 (2011).
22. Yeun Y, Lee J. Effect of a double-coated probiotic formulation on functional constipation in the elderly: a randomized, double blind, controlled study. Arch. Pharm. Res. 38(7), 1345-1350 (2015).
23. Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J. Gastroenterol. 20(27), 8886-8897 (2014).
24. Bixquert M. Treatment of irritable bowel syndrome with probiotics. Indian J. Med. Res. 138(2), 175-177 (2013).
25. Buckley MM, O'Mahony SM, O'Malley D. Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome. World J. Gastroenterol. 20(27), 8846-8858 (2014).
26. Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. Probiotics and irritable bowel syndrome. World J. Gastroenterol. 19(36), 5973-5980 (2013).
27. Yoon JS, Sohn W, Lee OY et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J. Gastroentrol. Hepatol. 29(1), 52-59 (2014).
28. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J. Pediatr. Gastroenterol. Nutr. 33(Suppl. 2), S17-S25 (2001).
29. Salari P, Nikfar S, Abdollahi M. A metaanalysis and systematic review on the effect of probiotics in acute diarrhea. Inflamm. Allergy Drug Targets 11(1), 3-14 (2012).
30. Applegate JA, Fischer Walker CL, Ambikapathi R, Black RE. Systematic review of probiotics for the treatment of community-acquired acute diarrhea in children. BMC Public Health 13(Suppl. 3), S16 (2013).
31. Cruchet S, Furnes R, Maruy A et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr. Drugs 17(3), 199-216 (2015).
32. Dinleyici EC, Dalgic N, Gven S et al. The effect of multispecies symbiotic mixture on the duration of diarrhea and length of hospital stay in children with acute diarrhea in Turkey: single blinded randomized study. Eur. J. Pediatr. 172(4), 459-464 (2013).
33. Watanabe S, Narisawa Y, Arase S et al. Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J. Allergy Clin. Immunol. 111(3) 587-591 (2003).
34. Baviera G, Leoni MC, Capra L et al. Microbiota in healthy skin and in atopic eczema. Biomed. Res. Int. 2014, 436921 (2014).
35. Isolauri E, Majamaa H, Arvola T, Rantala I, Virtanen E, Arvilommi H. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 105(6), 1643-1650 (1993).
36. Pessi T, Sütas Y, Hurme M, Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin. Exp. Allergy 30(12), 1804-1808 (2000).
37. Pohjavuori E, Viljanen M, Korpela R et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. J. Allergy Clin. Immunol. 114(1), 131-136 (2004).
38. Yim JH, Kim DH, Ku JAK et al. Therapeutic effects of probiotics in patients with atopic dermatitis. J. Microbiol. Biotechnol. 16(11), 1699-1705 (2006).
39. Muñoz N. Is Helicobacter pylori a cause of gastric cancer? An appraisal of the seroepidemiological evidence. Cancer Epidemiol. Biomarkers Prev. 3(5), 445-451 (1994).
40. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 61(5), 646-664 (2012).
41. Sahin O, Yesil A, Senates E et al. Synbiotic therapy increases eradication rate in Helicobacter pylori eradication. Acta Medica Mediterranea 29, 569-573 (2013).
42. Deshpande A, Pant C, Jain A, Fraser TG, Rolston DD. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr. Med Res. Opin. 24(2), 329-333 (2008).
43. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J. Gastroenterol. 15(13), 1554-1580 (2009).
44. Wiström J, Norrby SR, Myhre EB, Eriksson S, Granström G, Lagergren L et al. Frequency of antibiotic-associated diarrhea in 2462 antibiotic-treated hospitalized patients: a prospective study. J. Antimicrob. Agents Chemother. 47(1), 43-50 (2001).
45. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156(Pt 11), 3216-3223 (2010).
46. Jakobsson H, Wreiber K, Fall K, Fjelstad B, Nyrén O, Engstrand L. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand. J. Infect. Dis. 39(9), 757-763 (2007).